PsyMed Ventures is a San Francisco-based early-stage venture capital fund focused on brain and mental health technologies. It invests from pre-seed through Series A and covers a range of categories including psychedelics, neurotechnology, digital therapeutics, precision psychiatry, and AI-driven mental health approaches. Its thesis is explicitly centered on the future of brain health.

The fund is notable for bridging pharmacological and device-based approaches rather than treating them as separate worlds. That makes it particularly relevant to neurotech companies operating in psychiatry, mental health measurement, or treatment platforms that combine hardware, software, and biology. Its smaller size is offset by the clarity of its specialization.

PsyMed invests globally, with a primary US orientation. For neurotech founders, it is a strong thematic fit in mental health, precision psychiatry, BCI, and neurotechnology-adjacent treatment models. It stands out as a focused early-stage specialist rather than a broad healthcare generalist.